NASDAQ:CRDF Cardiff Oncology Q1 2026 Earnings Report $1.68 -0.06 (-3.18%) As of 10:39 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cardiff Oncology EPS ResultsActual EPS-$0.18Consensus EPS -$0.13Beat/MissMissed by -$0.05One Year Ago EPSN/ACardiff Oncology Revenue ResultsActual Revenue$0.04 millionExpected Revenue$0.09 millionBeat/MissMissed by -$48.00 thousandYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time7:00AM ETUpcoming EarningsCardiff Oncology's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, July 28, 2026 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Earnings HeadlinesCardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update1 hour ago | finanznachrichten.deCardiff Oncology Reports First Quarter 2026 Results and Provides Business UpdateMay 14 at 4:10 PM | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 15 at 1:00 AM | Weiss Ratings (Ad)Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent ActivityApril 27, 2026 | markets.businessinsider.comCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent ActivityApril 27, 2026 | globenewswire.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments. Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors. Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early InningsKarman: Defense Darling's Outlook Strengthens After 40% DropHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive Run Upcoming Earnings Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
